Panobinostat vs Purinostat Mesylate
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Multiple Myeloma
Shared mechanism: HDAC · full Multiple Myeloma pipeline
Panobinostat
Rights held by pharmaand and partners
NCT01023308 · Phase 3 · completed
PANORAMA-1 randomly assigned 768 patients with relapsed or relapsed and refractory multiple myeloma to panobinostat or placebo, each with bortezomib and dexamethasone, in a double-blind design. The primary endpoint, investigator-assessed progression-free survival, was met: median 11.99 versus 8.08 months, hazard ratio 0.63 (95% CI 0.52 to 0.76), p<0.0001, per the peer-reviewed publication. Overall survival did not differ significantly at that analysis (HR 0.87, p=0.26).
Reported efficacy
Progression-free Survival Events in Patients Treated With Panobinostat in Combination With Bortezomib and Dexamethasone vs. Patients Treated by Placebo in Combination With Bortezomib and Dexamethasone. (45 months); Progression Free Survival in Patients Treated With Panobinostat in Combination With Bortezomib and Dexamethasone vs. Patients Treated by Placebo in Combination With Bortezomib and Dexamethasone. (45 months): Progression-free survival (investigator-assessed): median 11.99 months with panobinostat + bortezomib + dexamethasone vs 8.08 months with placebo + bortezomib + dexamethasone; HR 0.63 (95% CI 0.52-0.76), p<0.0001 (Lancet Oncology 2014) (met)
Result source: NCT01023308
Purinostat Mesylate
Developed by Chengdu Zenitar Biomedical Technology
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
No aligned efficacy figure on record for this race.
Results for Multiple Myeloma
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | Panobinostat | Purinostat Mesylate |
|---|---|---|
| PFS, median | 12.0 vs 8.8+3.2 vs placeboNCT010233089 other results
| —Not reported |
| OS, median | 40.3 vs 35.8+4.5 vs placeboNCT010233088 other results
| —Not reported |
| ORR | 62.2%bNCT026549907 other results
| —Not reported |
| VGPR or better | —Not reported | —Not reported |
| MRD negativity | —Not reported | —Not reported |
PFS, median
- Panobinostat
- 12.0 vs 8.8+3.2 vs placeboNCT01023308
9 other results
- 15 NCT02654990
- 13 NCT02654990
- 3.7 NCT00918333
- 8 NCT02654990
- 4.2 NCT00918333
- 4.3 NCT00918333
- 2.3 NCT00918333
- 15.3 NCT02290431
- 5.4 NCT01083602
- Purinostat Mesylate
- —Not reported
OS, median
- Panobinostat
- 40.3 vs 35.8+4.5 vs placeboNCT01023308
8 other results
- 35 NCT02654990
- 32 NCT02654990
- 17.1 NCT00918333
- 22 NCT02654990
- 35.4 NCT00918333
- 18.4 NCT01083602
- 21.7 NCT00918333
- 16.6 NCT00918333
- Purinostat Mesylate
- —Not reported
ORR
- Panobinostat
- 62.2%bNCT02654990
7 other results
- 65.1% NCT02654990
- 50.6% NCT02654990
- 34.5% NCT01083602
- 62.2% NCT02654990
- 67.5% NCT02654990
- 53% NCT02654990
- 80.6% NCT02290431
- Purinostat Mesylate
- —Not reported
VGPR or better
- Panobinostat
- —Not reported
- Purinostat Mesylate
- —Not reported
MRD negativity
- Panobinostat
- —Not reported
- Purinostat Mesylate
- —Not reported
- b Single-arm result: the trial had no control arm, so the number has no comparator and does not compare with a randomised result.
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
Purinostat Mesylate: no structured comparison results are available for Multiple Myeloma.
Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.
safety
Coverage. Panobinostat: 4 of 4 rows · Purinostat Mesylate: 0 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | Panobinostat |
|---|---|
| Dropout rate | —PAN+BTZa NCT01023308 · Phase 3 · combination · Multiple Myeloma · phase 3 show 31 more results73.6%Panobinostat + Bortezomib NCT01023308 · Phase 3 · combination · Multiple Myeloma · phase 3 0%20 mg TIW NCT02654990 · Phase 2 · registry result, not featured evidence 0%20 mg BIW NCT02654990 · Phase 2 · registry result, not featured evidence 0%10 mg TIW NCT02654990 · Phase 2 · registry result, not featured evidence 87.1% NCT02290431 · Phase 2 · registry result, not featured evidence · combination 93.8% NCT01651039 · Phase 2 · registry result, not featured evidence · combination —PAN + BTZ + Dex NCT01083602 · Phase 2 · registry result, not featured evidence · combination n/a: no completion milestonePanobinostat + Bortezomib & Dexame NCT01083602 · Phase 2 · registry result, not featured evidence · combination 11.5%Phase I (Panobinostat + Everolimus NCT00918333 · Phase 1/2 · registry result, not featured evidence · combination 5.1%Phase II (Panobinostat + Everolimu NCT00918333 · Phase 1/2 · registry result, not featured evidence · combination — NCT00743288 · Phase 1/2 · registry result, not featured evidence · combination —80 mg NCT00621244 · Phase 1/2 · registry result, not featured evidence —80 mg NCT00621244 · Phase 1/2 · registry result, not featured evidence —60 mg NCT00621244 · Phase 1/2 · registry result, not featured evidence —60 mg NCT00621244 · Phase 1/2 · registry result, not featured evidence —60 mg NCT00621244 · Phase 1/2 · registry result, not featured evidence —60 mg NCT00621244 · Phase 1/2 · registry result, not featured evidence —45 mg NCT00621244 · Phase 1/2 · registry result, not featured evidence —45 mg NCT00621244 · Phase 1/2 · registry result, not featured evidence —40 mg NCT00621244 · Phase 1/2 · registry result, not featured evidence —40 mg NCT00621244 · Phase 1/2 · registry result, not featured evidence —30 mg NCT00621244 · Phase 1/2 · registry result, not featured evidence —30 mg NCT00621244 · Phase 1/2 · registry result, not featured evidence —30 mg NCT00621244 · Phase 1/2 · registry result, not featured evidence —30 mg NCT00621244 · Phase 1/2 · registry result, not featured evidence —20 mg NCT00621244 · Phase 1/2 · registry result, not featured evidence —20 mg NCT00621244 · Phase 1/2 · registry result, not featured evidence n/a: no completion milestoneArm 1, Group X NCT00621244 · Phase 1/2 · registry result, not featured evidence n/a: no completion milestoneArm 1, Group Y NCT00621244 · Phase 1/2 · registry result, not featured evidence n/a: no completion milestoneArm 2, Group X NCT00621244 · Phase 1/2 · registry result, not featured evidence n/a: no completion milestoneArm 2, Group Y NCT00621244 · Phase 1/2 · registry result, not featured evidence |
| Discontinued due to AEs | —PAN+BTZa NCT01023308 · Phase 3 · combination · Multiple Myeloma · phase 3 show 31 more results33.6%Panobinostat + Bortezomib NCT01023308 · Phase 3 · combination · Multiple Myeloma · phase 3 —20 mg TIW NCT02654990 · Phase 2 · registry result, not featured evidence —20 mg BIW NCT02654990 · Phase 2 · registry result, not featured evidence —10 mg TIW NCT02654990 · Phase 2 · registry result, not featured evidence 64.5% NCT02290431 · Phase 2 · registry result, not featured evidence · combination — NCT01651039 · Phase 2 · registry result, not featured evidence · combination —PAN + BTZ + Dex NCT01083602 · Phase 2 · registry result, not featured evidence · combination 20%Panobinostat + Bortezomib & Dexame NCT01083602 · Phase 2 · registry result, not featured evidence · combination —Phase I (Panobinostat + Everolimus NCT00918333 · Phase 1/2 · registry result, not featured evidence · combination —Phase II (Panobinostat + Everolimu NCT00918333 · Phase 1/2 · registry result, not featured evidence · combination — NCT00743288 · Phase 1/2 · registry result, not featured evidence · combination —80 mg NCT00621244 · Phase 1/2 · registry result, not featured evidence —80 mg NCT00621244 · Phase 1/2 · registry result, not featured evidence —60 mg NCT00621244 · Phase 1/2 · registry result, not featured evidence —60 mg NCT00621244 · Phase 1/2 · registry result, not featured evidence —60 mg NCT00621244 · Phase 1/2 · registry result, not featured evidence —60 mg NCT00621244 · Phase 1/2 · registry result, not featured evidence —45 mg NCT00621244 · Phase 1/2 · registry result, not featured evidence —45 mg NCT00621244 · Phase 1/2 · registry result, not featured evidence —40 mg NCT00621244 · Phase 1/2 · registry result, not featured evidence —40 mg NCT00621244 · Phase 1/2 · registry result, not featured evidence —30 mg NCT00621244 · Phase 1/2 · registry result, not featured evidence —30 mg NCT00621244 · Phase 1/2 · registry result, not featured evidence —30 mg NCT00621244 · Phase 1/2 · registry result, not featured evidence —30 mg NCT00621244 · Phase 1/2 · registry result, not featured evidence —20 mg NCT00621244 · Phase 1/2 · registry result, not featured evidence —20 mg NCT00621244 · Phase 1/2 · registry result, not featured evidence 31.4%Arm 1, Group X NCT00621244 · Phase 1/2 · registry result, not featured evidence 20.6%Arm 1, Group Y NCT00621244 · Phase 1/2 · registry result, not featured evidence 27.3%Arm 2, Group X NCT00621244 · Phase 1/2 · registry result, not featured evidence 8.7%Arm 2, Group Y NCT00621244 · Phase 1/2 · registry result, not featured evidence |
| Serious AEs | 59.8%PAN+BTZa NCT01023308 · Phase 3 · combination · Multiple Myeloma · phase 3 show 31 more results—Panobinostat + Bortezomib NCT01023308 · Phase 3 · combination · Multiple Myeloma · phase 3 56.4%20 mg TIW NCT02654990 · Phase 2 · registry result, not featured evidence 48.2%20 mg BIW NCT02654990 · Phase 2 · registry result, not featured evidence 45%10 mg TIW NCT02654990 · Phase 2 · registry result, not featured evidence 45.2% NCT02290431 · Phase 2 · registry result, not featured evidence · combination — NCT01651039 · Phase 2 · registry result, not featured evidence · combination 70.9%PAN + BTZ + Dex NCT01083602 · Phase 2 · registry result, not featured evidence · combination —Panobinostat + Bortezomib & Dexame NCT01083602 · Phase 2 · registry result, not featured evidence · combination 13%Phase I (Panobinostat + Everolimus NCT00918333 · Phase 1/2 · registry result, not featured evidence · combination 26.9%Phase II (Panobinostat + Everolimu NCT00918333 · Phase 1/2 · registry result, not featured evidence · combination 17.5% NCT00743288 · Phase 1/2 · registry result, not featured evidence · combination 90.9%80 mg NCT00621244 · Phase 1/2 · registry result, not featured evidence 88.9%80 mg NCT00621244 · Phase 1/2 · registry result, not featured evidence 69.4%60 mg NCT00621244 · Phase 1/2 · registry result, not featured evidence 40%60 mg NCT00621244 · Phase 1/2 · registry result, not featured evidence 77.8%60 mg NCT00621244 · Phase 1/2 · registry result, not featured evidence 73.3%60 mg NCT00621244 · Phase 1/2 · registry result, not featured evidence 88.9%45 mg NCT00621244 · Phase 1/2 · registry result, not featured evidence 42.9%45 mg NCT00621244 · Phase 1/2 · registry result, not featured evidence 41.7%40 mg NCT00621244 · Phase 1/2 · registry result, not featured evidence 90%40 mg NCT00621244 · Phase 1/2 · registry result, not featured evidence 75%30 mg NCT00621244 · Phase 1/2 · registry result, not featured evidence 62.5%30 mg NCT00621244 · Phase 1/2 · registry result, not featured evidence 83.3%30 mg NCT00621244 · Phase 1/2 · registry result, not featured evidence 0%30 mg NCT00621244 · Phase 1/2 · registry result, not featured evidence 0%20 mg NCT00621244 · Phase 1/2 · registry result, not featured evidence 100%20 mg NCT00621244 · Phase 1/2 · registry result, not featured evidence —Arm 1, Group X NCT00621244 · Phase 1/2 · registry result, not featured evidence —Arm 1, Group Y NCT00621244 · Phase 1/2 · registry result, not featured evidence —Arm 2, Group X NCT00621244 · Phase 1/2 · registry result, not featured evidence —Arm 2, Group Y NCT00621244 · Phase 1/2 · registry result, not featured evidence |
| Most frequent reported AEs | a diarrhoea 66.7% (placebo 41.1%) thrombocytopenia 62.5% (placebo 39.8%) fatigue 40.7% (placebo 28.9%) NCT01023308 · Phase 3 · combination · Multiple Myeloma · phase 3 show 24 more results20 mg TIW diarrhoea 65.4% thrombocytopenia 55.1% anaemia 42.3% NCT02654990 · Phase 2 · registry result, not featured evidence 20 mg BIW diarrhoea 63.9% thrombocytopenia 44.6% asthenia 34.9% NCT02654990 · Phase 2 · registry result, not featured evidence 10 mg TIW diarrhoea 48.8% thrombocytopenia 32.5% anaemia 30% NCT02654990 · Phase 2 · registry result, not featured evidence diarrhoea 80.6% decreased appetite 58.1% thrombocytopenia 54.8% NCT02290431 · Phase 2 · registry result, not featured evidence · combination diarrhoea 70.9% fatigue 67.3% nausea 60% NCT01083602 · Phase 2 · registry result, not featured evidence · combination hemoglobin decreased 95.7% platelet count decreased 95.7% fatigue 91.3% NCT00918333 · Phase 1/2 · registry result, not featured evidence · combination hemoglobin decreased 97.8% platelet count decreased 90.3% fatigue 89.2% NCT00918333 · Phase 1/2 · registry result, not featured evidence · combination neutropenia 27.5% thrombocytopenia 25% lymphopenia 22.5% NCT00743288 · Phase 1/2 · registry result, not featured evidence · combination 80 mg diarrhoea 90.9% fatigue 72.7% nausea 72.7% NCT00621244 · Phase 1/2 · registry result, not featured evidence 80 mg nausea 77.8% neutropenia 66.7% thrombocytopenia 66.7% NCT00621244 · Phase 1/2 · registry result, not featured evidence 60 mg diarrhoea 83.7% fatigue 73.5% anorexia 65.3% NCT00621244 · Phase 1/2 · registry result, not featured evidence 60 mg thrombocytopenia 100% fatigue 60% hypokalaemia 60% NCT00621244 · Phase 1/2 · registry result, not featured evidence 60 mg nausea 77.8% diarrhoea 66.7% vomiting 55.6% NCT00621244 · Phase 1/2 · registry result, not featured evidence 60 mg fatigue 80% nausea 80% thrombocytopenia 73.3% NCT00621244 · Phase 1/2 · registry result, not featured evidence 45 mg fatigue 66.7% diarrhoea 44.4% dyspnoea 44.4% NCT00621244 · Phase 1/2 · registry result, not featured evidence 45 mg fatigue 85.7% nausea 85.7% diarrhoea 71.4% NCT00621244 · Phase 1/2 · registry result, not featured evidence 40 mg thrombocytopenia 91.7% fatigue 79.2% nausea 66.7% NCT00621244 · Phase 1/2 · registry result, not featured evidence 40 mg nausea 90% vomiting 80% fatigue 70% NCT00621244 · Phase 1/2 · registry result, not featured evidence 30 mg thrombocytopenia 100% diarrhoea 75% lower respiratory tract infection 50% NCT00621244 · Phase 1/2 · registry result, not featured evidence 30 mg diarrhoea 62.5% fatigue 62.5% hypokalaemia 62.5% NCT00621244 · Phase 1/2 · registry result, not featured evidence 30 mg nausea 66.7% diarrhoea 50% fatigue 50% NCT00621244 · Phase 1/2 · registry result, not featured evidence 30 mg arthralgia 100% diarrhoea 100% epistaxis 100% NCT00621244 · Phase 1/2 · registry result, not featured evidence 20 mg arthralgia 100% back pain 100% fatigue 100% NCT00621244 · Phase 1/2 · registry result, not featured evidence 20 mg anorexia 62.5% diarrhoea 62.5% nausea 62.5% NCT00621244 · Phase 1/2 · registry result, not featured evidence |
Notes
- aPopulation comparability has not been reviewed for 30 of these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
Panobinostat
show 7 more results
show 2 more results
show 2 more results
show 2 more results
show 8 more results
show 8 more results
+ 16 further endpoints in the CSV export.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Panobinostat's landscape · Purinostat Mesylate's landscape